|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 急性缺血性卒中患者早期处理指南:美国心脏协会/美国卒中协会对医疗专业人员的指南(续前)显示文摘7静脉溶栓
7.1静脉rtPA
急性卒中的静脉溶栓治疗现已得到普遍接受。美国FDA于1996年批准静脉应用rtPA,部分基于NINDSrtPA卒中试验结果。 | Edward C. Jauch Jeffrey L. Saver Harold P. Adams Askiel Bruno J.J. (Buddy) Connors Bart M. Demaerschalk Pooja Khatri Paul W. McMullan Adnan I. Qureshi Kenneth Rosenfield Phillip A. Scott Debbie R. Summers David Z. Wang Max Wintermark Howard Yonas 李海峰(译) 岳耀先(译) 王琦(译) 张贤军(译) 丁晓君(译) | 2013 | 国际脑血管病杂志2013，21，8： | 975 |
| 2 | 中国卒中报告2019(中文版)(1)显示文摘中国卒中防治正面临巨大挑战。2018年,中国脑血管病的死亡率为149.49/10万,造成了157万人死亡。脑血管病是我国居民的第三位死亡原因,位列恶性肿瘤和心脏病之后。2013年,卒中年龄标化患病率和发病率分别为1114.8/10万和246.8/10万人年。根据2017年全球疾病负担研究,1990-2017年卒中造成的过早死亡损失寿命年(year of life lost,YLL)增加了14.6%,卒中由造成YLL的第三位原因跃升为第一位;卒中造成的全年龄组伤残调整生命年(disability-adjusted life year,DALY)的绝对数和百分率也呈持续增长趋势,2017年卒中是造成全年龄组DALY的首位原因。脑血管病的主要危险因素包括行为危险因素(如吸烟和酗酒)和既往疾病(如高血压、糖尿病、血脂异常和心房颤动)。卒中存活者中最普遍的危险因素是高血压(63.0%~84.2%)和吸烟(31.7%~47.6%),心房颤动的比例相对最低(2.7%~7.4%)。这些主要的危险因素在人群中流行水平也较高,并呈持续增长的趋势。根据最新的国家流行病学调查数据,我国15岁及以上人群的现在吸烟率为26.6%(现在吸烟人数为3.08亿)。18岁及以上人群的高血压年龄标化患病率为25.2%;高胆固醇血症的标化患病率为5.8%;糖尿病标化患病率为10.9%。40岁及以上人群心房颤动的标化患病率为2.31%。医院质量监测系统(Hospital Quality Monitoring System,HQMS)数据显示,2018年我国1853家三级医院共计收治3010204例卒中住院患者,其中2466785例(81.9%)为缺血性卒中(ischemic stroke,IS),447609例(14.9%)为脑出血(intracerebral hemorrhage,ICH),95810例(3.2%)为蛛网膜下腔出血(subarachnoid hemorrhage,SAH)。入院患者的平均年龄为66岁,近60%为男性。在IS、ICH和SAH中,分别有1555例(0.1%)、2774例(0.6%)和1347例(1.4%)为儿童卒中(年龄<18岁)。超过三分之一(1063892例,35.3%)患者的医保类型为城镇居民基本医疗保险,其次是城镇职工基本医疗保险(699513例,23.2%)和新型农村合作医疗保险(489361例,16.3%)。卒中患者的主要危险因素为高血压(IS:67.4%,ICH:77.2%,SAH:49.1%),主要并发症是肺炎或肺部感染(IS:10.1%,ICH:31.4%,SAH:25.2%)。卒中住院患者的死亡/非医嘱离院率为8.3%,从IS患者的5.8%到ICH患者的19.5%。住院时间的中位数(四分位数间距)为10.0(7.0~14.0)d,从IS患者的10.0(7.0~13.0)d到SAH患者的14.0(8.0~22.0)d。中国卒中中心联盟的数据显示,指南推荐的IS、ICH和SAH患者关键绩效指标执行的综合评分分别为0.77±0.21、0.72±0.28和0.59±0.32。 | 王拥军 李子孝 谷鸿秋 翟屹 姜勇 赵性泉 王伊龙 杨昕 王春娟 孟霞 李昊 刘丽萍 荆京 吴静 徐安定 董强 David Wang 赵继宗 无 | 2020 | 中国卒中杂志2020，15，10： | 174 |
| 3 | China Stroke Statistics 2019:A Report From the National Center for Healthcare Quality Management in Neurological Diseases,China National Clinical Research Center for Neurological Diseases,the Chinese Stroke Association,National Center for Chronic and Non-communicable Disease Control and Prevention,Chinese Center for Disease Control and Prevention and Institute for Global Neuroscience and Stroke Collaborations显示文摘China faces the greatest challenge from stroke in the world.The death rate for cerebrovascular diseases in China was 149.49 per 100000,accounting for 1.57 million deaths in 2018.It ranked third among the leading causes of death behind malignant tumours and heart disease.The age-standardised prevalence and incidence of stroke in 2013 were 1114.8 per 100000 population and 246.8 per 100000 person-years,respectively.According to the Global Burden of Disease Study 2017,the years of life lost(YLLs)per 100000 population for stroke increased by 14.6%;YLLs due to stroke rose from third highest among all causes in 1990 to the highest in 2017.The absolute numbers and rates per 100000 population for all-age disability-adjusted life years(DALYs)for stroke increased substantially between 1990 and 2017,and stroke was the leading cause of all-age DALYs in 2017.The main contributors to cerebrovascular diseases include behavioural risk factors(smoking and alcohol use)and pre-existing conditions(hypertension,diabetes mellitus,dyslipidaemia and atrial fibrillation(AF)).The most prevalent risk factors among stroke survivors were hypertension(63.0%-84.2%)and smoking(31.7%-47.6%).The least prevalent was AF(2.7%-7.4%).The prevalences for major risk factors for stroke are high and most have increased over time.Based on the latest national epidemiological data,26.6%of adults aged≥15 years(307.6 million adults)smoked tobacco products.For those aged≥18 years,age-adjusted prevalence of hypertension was 25.2%;adjusted prevalence of hypercholesterolaemia was 5.8%;and the standardised prevalence of diabetes was 10.9%.For those aged≥40 years,the standardised prevalence of AF was 2.31%.Data from the Hospital Quality Monitoring System showed that 3010204 inpatients with stroke were admitted to 1853 tertiary care hospitals during 2018.Of those,2466785(81.9%)were ischaemic strokes(ISs);447609(14.9%)were intracerebral haemorrhages(ICHs);and 95810(3.2%)were subarachnoid haemorrhages(SAHs).The average age of patients admitted was 66 years old,and nearly 60%were male.A total of 1555(0.1%),2774(0.6%)and 1347(1.4%)paediatric strokes(age<18 years)were identified among IS,ICH and SAH,respectively.Over one-third(1063892(35.3%))of the patients were covered by urban resident basic medical insurance,followed by urban employee basic medical insurance(699513(23.2%))and new rural cooperative medical schema(489361(16.3%)).The leading risk factor was hypertension(67.4%for IS,77.2%for ICH and 49.1%for SAH),and the leading comorbidity was pneumonia or pulmonary infection(10.1%for IS,31.4%for ICH and 25.2%for SAH).In-hospital death/discharge against medical advice rate was 8.3%for stroke inpatients,ranging from 5.8%for IS to 19.5%for ICH.The median and IQR of length of stay was 10.0(7.0-14.0)days,ranging from 10.0(7.0-13.0)in IS to 14.0(8.0-22.0)in SAH.Data from the Chinese Stroke Center Alliance demonstrated that the composite scores of guideline-recommended key performance indicators for patients with IS,ICH and SAH were 0.77±0.21,0.72±0.28 and 0.59±0.32,respectively. | Yong-Jun Wang Zi-Xiao Li Hong-Qiu Gu Yi Zhai Yong Jiang Xing-Quan Zhao Yi-Long Wang Xin Yang Chun-Juan Wang Xia Meng Hao Li Li-Ping Liu Jing Jing Jing Wu An-Ding Xu Qiang Dong David Wang Ji-Zong Zhao On behalf of China Stroke Statistics 2019 Writing Committee | 2020 | Stroke & Vascular Neurology2020，5，3： | 181 |
| 4 | 中国卒中报告2020(中文版)(1)显示文摘我国正面临着全球最大的卒中挑战。全球疾病负担(global burden of disease,GBD)研究结果显示,2019年我国新发卒中394万例,卒中患者达到2876万例,卒中死亡人数为219万例。此外,卒中也是我国伤残调整生命年(disability-adjusted life years,DALYs)的首位原因,2019年卒中所致DALYs达到4590万。近期的几项大型流行病学调查对与卒中有关的既往疾病数据进行了更新。2018年我国18~69岁成人的超重和肥胖率分别为34.4%和16.8%;18岁及以上无高血压病史的成人中50.9%处于高血压前期,成人高血压的加权患病率为27.5%。根据美国糖尿病学会诊断标准,2017年我国18岁及以上成人中,总糖尿病和糖尿病前期的加权患病率分别为12.8%和35.2%;45岁以上成人的心房颤动加权患病率为1.8%,患者人数相当于790万人。医院质量监测系统(hospital quality monitoring system,HQMS)中1672家三级公立医院的数据显示,2019年收治卒中病例3411168例,其中缺血性卒中(ischemic stroke,IS)2818875例(82.6%),脑出血(intracebral hemorrhage,ICH)485474例(14.2%),蛛网膜下腔出血(subarachnoid hemorrhage,SAH)106819例(3.1%)。中位年龄为66岁,59.6%为男性。在IS、ICH和SAH中儿童卒中(年龄<18岁)分别有1379例(<0.1%)、2604例(0.5%)和1250例(1.2%)。超过三分之一[1231519例(36.1%)]的卒中病例参加了城镇居民基本医疗保险,其次是城镇职工基本医疗保险[891103例(26.1%)]和新型农村合作医疗保险[543108例(15.9%)]。主要危险因素是高血压(IS 57.3%、ICH 69.9%、SAH 44.1%),主要并发症是肺炎或肺部感染(IS 10.4%、ICH 34.6%、SAH29.7%)。总体的院内死亡/非医嘱离院率为8.5%,从IS的6.0%到SAH的20.6%不等。住院时间为9.0(6.0~13.0)d,范围从IS的10.0(7.0~13.0)d到ICH的14.0(8.0~22.0)d。HQMS中2847家二级公立或民营医院的数据也有类似的结果。HQMS的数据显示,内蒙古自治区、安徽省、西藏自治区和北京市去外省就医比例较高。北京市、天津市、上海市和宁夏回族自治区等省外来诊患者比例较高。2019年中国卒中中心联盟(Chinese Stroke Center Alliance,CSCA)联合1337家医院进行了调查,汇总323601例卒中数据显示,指南推荐的IS、ICH和SAH患者关键绩效指标综合评分分别为0.78±0.20分、0.69±0.27分和0.60±0.31分。 | 王拥军 李子孝 谷鸿秋 翟屹 姜勇 周齐 赵性泉 王伊龙 杨昕 王春娟 孟霞 李昊 刘丽萍 荆京 吴静 徐安定 董强 David Wang 王文志 马旭东 赵继宗 《中国卒中报告》编写委员会 | 2022 | 中国卒中杂志2022，17，5： | 123 |
| 5 | The Global Boundary Stratotype Section and Point (GSSP) for the base of the Hirnantian Stage (the uppermost of the Ordovician System)显示文摘 | Xu Chen Jiayu Rong Junxuan Fan Renbin Zhan Charles E. Mitchell David A. T. Harper Michael J. Melchin Ping'an Peng Stan C. Finney Xiaofeng Wang | 2006 | Episodes2006，29，3： | 61 |
| 6 | aunalysis of the Genome Sequence of the Medicinal Plant Salvia miltiorrhiza显示文摘 | Haibin Xu Jingyuan Song Hongmei Luo Yujun Zhang Qiushi Li Yingjie Zhu Jiang Xu Ying Li Chi Song Bo Wang Wei Sun Guoan Shen Xin Zhang Jun Qian Aijia Ji Zhichao Xu Xiang Luo Liu He Chuyuan Li Chao Sun Haixia Yah Guanghong Cui Xiwen Li Xian 'en Li Jianhe Wei Juyan Liu Yitao Wang Alice Hayward David Nelson Zemin Ning Reuben J. Peters Xiaoquan Qi Shilin Chen | 2016 | Molecular Plant2016，9，6： | 70 |
| 7 | Trend of declining stroke mortality in China:reasons and analysis显示文摘Introduction There is a downward trend of stroke-related mortality in the USA.By reviewing all published articles on stroke mortality in China,we analysed its trend and possible factors that have influenced the trend.Methods Both English and Chinese literatures were searched on the mortality of stroke or cerebrovascular diseases in China.Potential papers related to this topic were identified from PubMed,Medline,Embase,Cochrane Library,Wanfang Database,SINOMED and China National Knowledge Infrastructure databases.Results Comparing the results from the most recent population-based epidemiological survey and databank from the national Center for Disease Control and Prevention,the age-adjusted stroke mortality rate has shown a downward trend among both urban and rural population in the past 30 years in China.Comparing with 30 years ago,the rate of stroke mortality has decreased by more than 31%in urban/suburban population and 11%in rural population.In men,the age-adjusted stroke mortality rate decreased by 18.9%and in women by 24.9%between 1994 and 2013.Factors that may have contributed to the trend of decreased stroke mortality rate include(1)improved healthcare coverage and healthcare environment;(2)improved treatment options and medical technology;(3)support by government to educate the public on stroke and stroke prevention;and(4)improved public knowledge on stroke.Conclusions The age-adjusted stroke mortality rate in China has shown a downward trend among both urban and rural population in the past 30 years.The major influencing factors that helped in reducing stroke mortality in China included improved healthcare coverage,healthcare environment,the updated treatment options and modern medical technology. | Wenzhi Wang David Wang Hongmei Liu Haixin Sun Bin Jiang Xiaojuan Ru Dongling Sun Zhenghong Chen Yongjun Wang | 2017 | Stroke & Vascular Neurology2017，2，3： | 52 |
| 8 | 中国卒中报告2019(中文版)(3)显示文摘(接上期)2.4院内管理我们首次依据国家指南利用中国卒中中心联盟2018年数据分析了卒中关键绩效指标。来自1377家医院的297327例卒中患者(缺血性卒中269428例、脑出血24556例和蛛网膜下腔出血3343例)纳入分析。缺血性卒中、脑出血和蛛网膜下腔出血患者绩效指标的复合指标评分分别为0.77±0.21、0.72±0.28和0.59±0.32。复合指标完全执行率分别为27.1%(26.9%~27.3%)、37.3%(36.7%~37.9%)和25.3%(23.9%~26.8%)。 | 王拥军 李子孝 谷鸿秋 翟屹 姜勇 赵性泉 王伊龙 杨昕 王春娟 孟霞 李昊 刘丽萍 荆京 吴静 徐安定 董强 David Wang 赵继宗 无 | 2020 | 中国卒中杂志2020，15，12： | 40 |
| 9 | Chinese Stroke Center Alliance:a national effort to improve healthcare quality for acute stroke and transient ischaemic attack:rationale,design and preliminary findings显示文摘Background In June 2015,the Chinese Stroke Association(CSA)initiated the Chinese Stroke Center Alliance(CSCA)to establish the national hospital-based stroke care quality assessment and improvement platform.This article outlines its objectives,operational structure,patient population,quality improvement(QI)intervention tools,data elements,data collection methodology and current patient and hospital data.Methods The CSCA is a national,hospital-based,multicentre,voluntary,multifaceted intervention and continuous QI initiative.This multifaceted intervention includes stroke centre development,written care protocols,workshops and a monitoring/feedback system of evidencebased performance measures.The data coordinating centre of the CSCA resides at the China National Clinical Research Center for Neurological Diseases,Beijing Tiantan Hospital.results As of July 2017,1576 hospitals in China have contributed detailed clinical information to serve as a benchmark for the stroke care quality of 433264 patients with acute stroke/transient ischaemic attacks(TIA),including 352572(81.38%)acute ischaemic stroke,30362(7.01%)TIA,42080(9.71%)spontaneous intracranial haemorrhage,5505(1.27%)subarachnoid haemorrhage and 2745(0.63%)not specified stroke.Conclusion The CSCA programme is designed to establish a continuous national stroke registry and help healthcare providers develop stroke centres and treat patients in a consistent manner in accordance with accepted national guidelines and,ultimately,improve patient outcomes.It supports the CSA mission to reduce stroke burden in China. | Yongjun Wang Zixiao Li Yilong Wang Xingquan Zhao Liping Liu Xin Yang Caiyun Wang Hongqiu Gu Fuying Zhang Chunjuan Wang Ying Xian David Z Wang Qiang Dong Anding Xu Jizong Zhao Chinese Stroke Center Alliance investigators | 2018 | Stroke & Vascular Neurology2018，3，4： | 38 |
| 10 | FXR: a metabolic regulator and cell protector显示文摘Farnesoid X 受体(FXR ) 是激活 ligand 的抄写因素的原子受体总科的一个成员。作为一个新陈代谢的管理者, FXR 戏在胆汁酸,胆固醇,类脂化合物,和葡萄糖新陈代谢给角色调音。因此, FXR 是为很多新陈代谢的混乱的一个潜在的药目标,特别那些与新陈代谢的症候群有关。更最近,我们的组和其它扩大了 FXR 的功能到非常新陈代谢的规定,它在肠,肝新生,和 hepatocarcinogenesis 包括抗菌剂生长。这些新调查结果比以前想建议 FXR 有宽广得多的角色,并且也为多重疾病作为一个药目标加亮 FXR。这评论总结 FXR 的基本信息,但是集中于它的新功能。 | Yan-Dong Wang Wei-Dong Chen David D Moore Wendong Huang | 2008 | Cell Research2008，18，11： | 33 |
| 11 | Biochemical mechanisms in drug-induced liver injury:Certainties and doubts显示文摘Drug-induced liver injury is a significant and still unresolved clinical problem.Limitations to knowledge about the mechanisms of toxicity render incomplete the detection of hepatotoxic potential during preclinical development.Several xenobiotics are lipophilic substances and their transformation into hydrophilic compounds by the cytochrome P-450 system results in production of toxic metabolites.Aging,preexisting liver disease,enzyme induction or inhibition,genetic variances,local O2 supply and,above all,the intrinsic molecular properties of the drug may affect this process.Necrotic death follows antioxidant consumption and oxidation of intracellular proteins,which determine increased permeability of mitochondrial membranes,loss of potential,decreased ATP synthesis,inhibition of Ca2+-dependent ATPase,reduced capability to sequester Ca2+ within mitochondria,and membrane bleb formation.Conversely,activation of nucleases and energetic participation of mitochondria are the main intracellular mechanisms that lead to apoptosis.Non-parenchymal hepatic cells are inducers of hepatocellular injury and targets for damage.Activation of the immune system promotes idiosyncratic reactions that result in hepatic necrosis or cholestasis,in which different HLA genotypes might play a major role.This review focuses on current knowledge of the mechanisms of drug-induced liver injury and recent advances on newly discovered mechanisms of liver damage.Future perspectives including new frontiers for research are discussed. | Ignazio Grattagliano Leonilde Bonfrate Catia V Diogo Helen H Wang David QH Wang Piero Portincasa | 2009 | World Journal of Gastroenterology2009，15，39： | 30 |
| 12 | Cosmogenic ^(10)Be dating of Guxiang and Baiyu Glaciations显示文摘Guxiang and Baiyu Glaciations are two previously recognized local glaciations of the Tibetan Plateau. They have been widely used as the reference standard for classifying Late Quaternary glaciations on the Tibetan Plateau and its surrounding mountains. However, the numerical chronologies of both glaciations have been lacking. In this study, cosmogenic 10Be dating was undertaken to define the timing of these two glaciations. The surface boulders deposited by the glaciers of the Guxiang and Baiyu Glaciations have exposure ages of 112.9±16.7―136.5±15.8 ka BP and 11.1±1.9―18.5±2.2 ka BP, respectively. It is likely that the Guxiang and Baiyu Glaciations correspond to marine isotope stages 6 and 2, respectively. | ZHOU ShangZhe XU LiuBing PATRICK M. Colgan DAVID M. Mickelson WANG XiaoLi WANG Jie ZHONG Wei | 2007 | Chinese Science Bulletin2007，52，10： | 28 |
| 13 | HYDRAULIC RESISTANCE OF SUBMERGED VEGETATION RELATED TO EFFECTIVE HEIGHT显示文摘Submerged vegetation has a significant impact on water flow velocity.Current investigations include the impact through adding drag resistance and increasing bottom roughness coefficient,which cannot elucidate the characters of real submerged vegetation.To evaluate the effects of submerged vegetation on water currents at different velocities,a laboratory experiment was conducted using three kinds of vegetations.The effective heights of these vegetations on varying flow velocities were evaluated.An equation describing the relationship between the normalized resistance of the submerged plants and the Reynolds number based on the plant effective height was then established and used to calculate the hydraulic resistance parameters of submerged plants in different stages of growth. | WANG Pei-fang WANG Chao ZHU David Z. | 2010 | Journal of Hydrodynamics2010，22，2： | 24 |
| 14 | Intracellular HMGB1 as a novel tumor suppressor of pancreatic cancer显示文摘尽管有最近的进展, oncogenic K 地岬驾驶的胰腺的 ductal 腺癌(PDAC ) 在最致命的人的癌症之中留在现代医学。PDAC 的致病对内在的染色体不稳定性和外来的发炎激活部分可归因。然而,在在胰腺的 tumorigenesis 的这二个事件之间的分子的连接充分还没被建立了。这里,我们证明(HMGB1 ) 细胞内部的高活动性组盒子 1 显著地压制 oncogenic 由禁止染色体的 K-Ras-driven 胰腺的 tumorigenesis 调停不稳定性的支持 inflammatory nucleosome 版本。任何一个单身者的有条件的基因脱离或在胰的 HMGB1 的两等位基因在出生使老鼠变为极其敏感到先锋损害的 oncogenic K-Ras-driven 开始,包括胰腺的 intraepithelial 瘤, intraductal 乳突的 mucinous 瘤,和 mucinous 膀胱的瘤。在胰的 HMGB1 的损失与染色体重新整理和 telomere 畸形描绘的氧化 DNA 损坏和 chromosomal 不稳定性被联系。这些导致煽动性的 nucleosome 版本并且宣传 K-Ras-driven 胰腺的 tumorigenesis。细胞外的 nucleosomes 支持 interleukin 6 (IL-6 ) 由渗入 macrophages/neutrophils 的分泌物并且提高在胰腺的损害表明激活的 oncogenic K 地岬。到 IL-6 或 histone H3 或为先进 glycation 的受体的大美人的抵销的抗体结束产品都限制表明激活的 K 地岬,阻止癌症开发和转移 / 侵略,并且延长在 Pdx1-Cre 的动物幸存; K 地岬 G12D/+;Hmgb1/ 鼠标。由 glycyrrhizin 的 HMGB1 损失的药理学抑制在煽动性的条件下面在老鼠限制 oncogenic K-Ras-driven tumorigenesis。减少在 PDAC 病人的 HMGB1 的原子、全部的细胞的表示与差的全面幸存相关,在 PDAC 与预示、治疗学的关联作为新奇肿瘤 suppressor 支持细胞内部的 HMGB1。 | Rui Kang Yangchun Xie Qiuhong Zhang Wen Hou Qingping Jiang Shan Zhu Jinbao Liu Dexing Zeng Haichao Wang David L Bartlet Timothy R Billiar Herbert J Zeh III Michael T Lotze Daolin Tang | 2017 | Cell Research2017，27，7： | 22 |
| 15 | Acute cerebrovascular disease following COVID-19: a single center, retrospective, observational study显示文摘Background and purpose COVID-19 is an infectious disease caused by Severe Acute Respiratory Syndrome Coronavirus 2(SARS-CoV-2).Apart from respiratory complications,acute cerebrovascular disease(CVD)has been observed in some patients with COVID-19.Therefore,we described the clinical characteristics,laboratory features,treatment and outcomes of CVD complicating SARS-CoV-2 infection.Materials and methods Demographic and clinical characteristics,laboratory findings,treatments and clinical outcomes were collected and analysed.Clinical characteristics and laboratory findings of patients with COVID-19 with or without new-onset CVD were compared.Results Of 219 patients with COVID-19,10(4.6%)developed acute ischaemic stroke and 1(0.5%)had intracerebral haemorrhage.COVID-19 with new onset of CVD were significantly older(75.7±10.8 years vs 52.1±15.3 years,p<0.001),more likely to present with severe COVID-19(81.8%vs 39.9%,p<0.01)and were more likely to have cardiovascular risk factors,including hypertension,diabetes and medical history of CVD(all p<0.05).In addition,they were more likely to have increased inflammatory response and hypercoagulable state as reflected in C reactive protein(51.1(1.3-127.9)vs 12.1(0.1-212.0)mg/L,p<0.05)and D-dimer(6.9(0.3-20.0)vs 0.5(0.1-20.0)mg/L,p<0.001).Of 10 patients with ischemic stroke;6 received antiplatelet treatment with aspirin or clopidogrel;and 3 of them died.The other four patients received anticoagulant treatment with enoxaparin and 2 of them died.As of 24 March 2020,six patients with CVD died(54.5%).Conclusion Acute CVD is not uncommon in COVID-19.Our findings suggest that older patients with risk factors are more likely to develop CVD.The development of CVD is an important negative prognostic factor which requires further study to identify optimal management strategy to combat the COVID-19 outbreak. | Yanan Li Man Li Mengdie Wang Yifan Zhou Jiang Chang Ying Xian David Wang Ling Mao Huijuan Jin Bo Hu | 2020 | Stroke & Vascular Neurology2020，5，3： | 22 |
| 16 | Therapy of gallstone disease:What it was,what it is,what it will be显示文摘Cholesterol gallstone disease is a common clinical condition influenced by genetic factors,increasing age,female gender,and metabolic factors.Although laparoscopic cholecystectomy is currently considered the gold standard in treating patients with symptomatic gallstones,new perspectives regarding medical therapy of cholelithiasis are currently under discussion,also taking into account the pathogenesis of gallstones,the natural history of the disease and the analysis of the overall costs of therapy.A careful selection of patients may lead to successful nonsurgical therapy in symptomatic subjects with a functioning gallbladder harboring small radiolucent stones.The classical oral litholysis by ursodeoxycholic acid has been recently paralleled by new experimental observations,suggesting that cholesterol-lowering agents which inhibit cholesterol synthesis (statins) or intestinal cholesterol absorption (ezetimibe),or drugs acting on specific nuclear receptors involved in cholesterol and bile acid homeostasis,might be proposed as additional approaches for treating cholesterol gallstones.In this review we discuss old,recent and future perspectives on medical treatment of cholesterol cholelithiasis. | Piero Portincasa Agostino Di Ciaula Leonilde Bonfrate David QH Wang | 2012 | World Journal of Gastrointestinal Pharmacology and Therapeutics2012，3，2： | 21 |
| 17 | Degradation of organic pollutants by a Co_3O_4 -graphite composite electrode in an electro-Fenton-like system显示文摘A novel composite electrode was constructed by pressing together Co3O4 and graphite and it was used as the cathode in an electro-Fenton-like (EFL) system. The poor electron transport characteristic of Co3O4 was overcome by incorporating graphite. In situ electro-catalytic generation of hydroxyl radicals (·OH) occurred at high current efficiencies from pH 2-10, extending the traditional Fenton reaction pH range. Cyclic voltammetry and AC impedance spectrometry were used to characterize the composite electrode. The ability of the EFL system to degrade organic compounds was investigated using sulforhodamine B (SRB) and 2,4-dichlorophenol (2,4-DCP) as probes. Decoloration of SRB (1.0×10-5 mol/L) was complete (100%) in 150 min and SRB was effectively degraded from pH 2-10. The decomposition of SRB was studied using Fourier transform infrared spectroscopy (FT-IR) and total organic carbon (TOC) analysis and results indicated that the final degradation products were carbon dioxide, carboxylic acids and amines. The EFL system also decomposed 2,4-DCP and the degradation was 98.6% in 240 min. Electro-catalytic degradation of SRB occurs by a ·OH mechanism. After 5 times reused, the degradation rate of SRB did not significantly slow down. The electrode shows excellent potential for use in advanced oxidation processes (AOPs) used to treat persistent organic pollutants (POPs) in wastewater. | LIU Shuan GU Yan WANG ShuLian ZHANG Yu FANG YanFen JOHNSON David M HUANG YingPing | 2013 | Chinese Science Bulletin2013，58，19： | 18 |
| 18 | 2018年中国卒中管理及研究进展显示文摘中国是世界上最大的卒中负担国。随着卒中医疗质量的进步,我国卒中死亡率呈下降趋势,但卒中发生率仍呈上升趋势。近年来,中国在卒中教育、研究和护理方面均取得了巨大成就。本文回顾了近年来有影响力的学术成就,对中国卒中医疗质量提升、溶栓及新的治疗方法探索、中国卒中建设发展等最新进展进行了总结和评价,并展望了中国卒中管理的未来。 | 刘丽萍 李曼 刘婧伊 杨中华 王伊龙 David Wang 王拥军 | 2019 | 临床荟萃2019，34，1： | 18 |
| 19 | 急性缺血性卒中患者早期处理指南:美国心脏协会/美国卒中协会对医疗专业人员的指南显示文摘背景和目的作者提供了关于成年急性缺血性卒中患者评估和治疗方面的现有证据和处理推荐的一份概述。目标读者为涉及急性缺血性卒中患者发病48h内诊治的院前诊疗人员、医生、综合医疗保健人员和医院管理者。该指南将取代先前的2007年版指南及其2009年更新版。方法著述委员会成员由美国卒中协会卒中委员会的科学声明监督委员会指定,代表各个领域的医疗专家。在形成共识的整个过程中,严格遵循美国心脏协会的利益冲突原则。委员会成员被分配给与其专业领域相关的内容,对卒中文献进行回顾,重点为前一版指南发表之后的文献,然后按照美国心脏协会卒中委员会的证据强度分级方案起草推荐意见。结果本指南的目的是减少卒中相关的残疾和死亡。本指南支持卒中医疗体系的全局性概念以及从患者识别、急救医疗服务激活、转送和分诊到急诊室和卒中单元内最初数小时诊治的卒中诊治细节。本指南讨论了早期卒中评估和一般治疗、缺血性卒中治疗、特殊干预措施,如再灌注策略以及脑复苏的一般生理学干预原则。结论由于许多推荐意见基于有限的证据,还迫切需要对急性缺血性卒中的治疗做进一步的研究。 | Edward C. Jauch Jeffrey L. Saver Harold P. Adams Askiel Bruno J.J. (Buddy) Connors Bart M. Demaerschalk Pooja Khatri Paul W. McMullan Jr, Adnan I. Qureshi Kenneth Rosenfield Phillip A. Scott Debbie R. Summers David Z. Wang Max Wintermark Howard Yonas 李海峰(译) 岳耀先(译) 王琦(译) 张贤军(译) 丁晓君(译) | 2013 | 国际脑血管病杂志2013，21，7： | 17 |
| 20 | 中国卒中报告2019(中文版)(2)显示文摘(接上期)2.2一般人群危险因素流行情况2.2.1行为因素2.2.1.1吸烟/烟草使用根据中国成人烟草调查2018年结果,≥15岁人群现在吸烟率为26.6%(现在吸烟者人数为3.08亿),其中,男性为50.5%,女性为2.1%。现在吸烟人群的23.2%(每日吸烟者人数为2.69亿)为每日吸烟者,其中男性占44.4%,女性占1.6%。50.9%室内工作的成人(2.17亿)在工作场所接触二手烟。44.9%的成人(5.15亿)在家中接触二手烟(表6和图7)。 | 王拥军 李子孝 谷鸿秋 翟屹 姜勇 赵性泉 王伊龙 杨昕 王春娟 孟霞 李昊 刘丽萍 荆京 吴静 徐安定 董强 David Wang 赵继宗 无 | 2020 | 中国卒中杂志2020，15，11： | 17 |
您所在的机构暂未开通此部分的功能，请联系管理员